Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCE-MRI Pharmacodynamic Study of Sorafenib in Metastatic RCC
NCT00606866Phase 3Completed
- Sponsor
- University of Chicago
- Start
- Jul 2004
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sorafenib in metastatic renal cell carcinoma (mRCC) (3 arms), sponsored by University of Chicago. Primary endpoint: Determine best dose of sorafenib using DCE-MRI at 8 weeks. Started Jul 2004; status: completed.
02
Drugs
sorafenib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00606866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00606866.